Cargando…

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Background and Aim: As one of the second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors, afatinib brings survival benefits to patients with common and rare EGFR mutations. This study aimed to compare the effectiveness and safety of 30 and 40 mg of afatinib in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ziyu, Du, Xin, Chen, Ken, Li, Shanshan, Yu, Zhiheng, Wu, Ziyang, Yang, Li, Chen, Dingding, Liu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666963/ https://www.ncbi.nlm.nih.gov/pubmed/34912228 http://dx.doi.org/10.3389/fphar.2021.781084

Ejemplares similares

Impact of the Gastric Acid Suppressant Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis
por: Du, Xin, et al.
Publicado: (2022)

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
por: Takahashi, Takayuki, et al.
Publicado: (2021)

Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients
por: Liu, Xiao, et al.
Publicado: (2021)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non‐small cell lung cancer
por: Nie, Xin, et al.
Publicado: (2021)

Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma
por: Zhou, Yongxu, et al.
Publicado: (2023)

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
por: Jin, Hui, et al.
Publicado: (2023)

Effects of Pharmacist-Led Clinical Pathway/Order Sets on Cancer Patients: A Systematic Review
por: Tan, Zhiyuan, et al.
Publicado: (2021)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
por: Chen, Can, et al.
Publicado: (2021)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
por: Li, Xinyi, et al.
Publicado: (2021)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
por: Liu, Zhen, et al.
Publicado: (2022)

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
por: Chai, Qing-Qing, et al.
Publicado: (2019)

Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis
por: Wei, Qiran, et al.
Publicado: (2023)

The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis
por: Zhou, Niya, et al.
Publicado: (2020)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Chi, et al.
Publicado: (2019)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Xin, et al.
Publicado: (2021)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
por: Du, Xin-Yuan, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies
por: Zhang, Yatong, et al.
Publicado: (2023)

Prevalence of polypharmacy and potentially inappropriate medication use in older lung cancer patients: A systematic review and meta-analysis
por: Tian, Fangyuan, et al.
Publicado: (2022)

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
por: Zhang, Lemeng, et al.
Publicado: (2021)

Huisheng Oral Solution Adjunct With Platinum-Based Chemotherapy for the Treatment of Advanced Non–Small Cell Lung Cancer: A Meta-Analysis and Systematic Review
por: Huang, Jingyi, et al.
Publicado: (2020)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
por: Zhu, Xiaoxi, et al.
Publicado: (2021)

Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis
por: Zheng, Zeyi, et al.
Publicado: (2023)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials
por: Peng, Ciyan, et al.
Publicado: (2022)

Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer
por: Chen, Ru, et al.
Publicado: (2021)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
por: Chen, Wei, et al.
Publicado: (2023)

Investigation on the Efficiency of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Vinorelbine and Cisplatin Based on Multidimensional Bayesian Network Meta-Analysis
por: Ni, Mengwei, et al.
Publicado: (2021)

Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Maarof, Nian N. N., et al.
Publicado: (2021)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
por: Hashida, Shinsuke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f4muqu9bj04fjieam959lmifm1